Overview of Ginalgin

Ginalgin: Overview and Quick Facts

Property	Description
Active Ingredients	Metronidazole (INN) and Chlorquinaldol (INN)
Form	Vaginal Tablets (Solid dosage form)
Pharmacological Class	Combination Anti-infective/Antimicrobial
Route	Local (Intravaginal)
Origin	Synthetic
Distinguishing Feature	Dual-action approach for broad-spectrum local coverage

What is Ginalgin and What is its Form?

Ginalgin is a specific brand of a combination medicine formulated as Vaginal Tablets for local administration, developed to address a broad range of infections. It is designed for intravaginal application, allowing the medicine to target the site of the infection directly. Unlike oral medications, this local application strategy is clinically recognized for optimizing antimicrobial therapy at the required site. The tablet form is a distinguishing feature, designed to dissolve slowly and release its agents over time within the affected environment.

What Active Ingredients Does Ginalgin Contain?

Ginalgin contains two distinct synthetic active ingredients: Metronidazole and Chlorquinaldol. It is classified as a combination product, merging two agents to offer broad-spectrum coverage. Metronidazole is widely recognized as a potent nitroimidazole antimicrobial agent, while Chlorquinaldol contributes an additional spectrum of activity, historically used as a topical antiseptic. This dual approach is a key differentiating factor from single-agent products, making it suitable for managing conditions where the infection may be caused by multiple types of pathogens.

What is the General Purpose of its Action?

The primary goal of Ginalgin's action is the elimination of the harmful microorganisms causing the infection directly at the application site. The medicine's combined antimicrobial and antiprotozoal activity aims to clear the underlying infection. By successfully removing these pathogens, Ginalgin helps relieve associated discomfort and aids in restoring a healthier balance to the affected environment, offering a foundational step toward recovery.

What side effects are possible with Ginalgin?

Possible Side Effects and Safety Information

Ginalgin, a combination product for vaginal use containing metronidazole and chlorquinaldol, is associated with both local and systemic adverse reactions, primarily due to the absorption of metronidazole.

Adverse Reactions and Categorization

Many documented side effects are formally classified as Frequency not known (cannot be estimated from available data). Common and local reactions may include vaginal irritation, itching, burning, discharge, and discomfort in the pelvic area. Systemic effects reported include headache, abdominal pain, nausea, vomiting, metallic or unpleasant taste, dizziness, and dark urine.

System-Organ Class	Examples of Reported Reactions
Nervous System	Headache, dizziness, abnormal sensations, depression, sleep disturbances, confusion.
Gastrointestinal	Abdominal discomfort, nausea, vomiting, metallic taste, diarrhea, dry mouth.
Genitourinary	Local irritation, burning, vaginal itching, discharge, menstrual disturbances.

Serious and Clinically Significant Risks

Serious neurological adverse reactions are possible, particularly those associated with the metronidazole component in other formulations. These include convulsive seizures, encephalopathy, aseptic meningitis, and peripheral neuropathy (numbness, tingling, or pain in the extremities). Patients must discontinue treatment immediately if any abnormal neurological signs appear. Additionally, the chlorquinaldol component carries a warning that prolonged use of high doses may cause sensory disturbances and vision disorders (subacute optic neuropathy).

Restrictions and Special Considerations

Alcohol Restriction: Consumption of alcoholic beverages is contraindicated during treatment and for at least 24–72 hours after the final dose due to the risk of a disulfiram-like reaction (flushing, vomiting, nausea, headaches).
Contraindications: Ginalgin is contraindicated in patients with a known hypersensitivity to the active substances or any excipient. It is also contraindicated for concurrent use with the drug disulfiram.
Population Warnings: The medicine is not recommended for use in children and adolescents under 18 years of age. Use during pregnancy is advised only if strictly necessary. Caution is required in patients with a history of severe liver failure or Central Nervous System diseases.

Overdose and Emergency Response

The official overdose profile for Ginalgin is based on the systemic toxicity documented in regulatory labeling for its active components, primarily Metronidazole. Any suspected overdose requires immediate professional medical intervention.

Documented Overdose Manifestations

Regulatory documents list specific clinical signs that may follow overexposure. These documented manifestations include gastrointestinal effects such as nausea and vomiting. Additionally, central nervous system (CNS) effects, specifically ataxia (loss of coordination), are noted in the official profile for the systemically active ingredient.

Severe Outcomes and Emergency Action

Overexposure is associated with the potential for serious outcomes, as described in official labeling. The regulatory profile formally lists severe CNS manifestations, including convulsive seizures and the development of peripheral neuropathy (numbness or paresthesia). Given the seriousness of these potential outcomes, regulatory guidance mandates specific emergency actions. Immediate medical attention is required upon suspicion of overdose. The instruction is to contact a poison control center or emergency room at once.

Management for overexposure is described as symptomatic and supportive therapy only, as there is no specific antidote known according to regulatory documentation. The appearance of any abnormal neurological signs demands prompt medical evaluation and potential hospital monitoring.

Therapeutic Uses of Ginalgin

What Ginalgin Treats: Main Uses and Benefits

Focused Symptom and Condition Management

The core therapeutic area for this medication involves anti-infective support for vaginal conditions. Ginalgin is commonly used for the local management of infectious vaginitis caused by susceptible microorganisms. This may involve treatment for conditions like Bacterial Vaginosis (BV) and the protozoal infection Trichomonas vaginalis, making it applicable within clinical settings that involve acute or disruptive symptom patterns.

The medication is used in situations involving certain distressing symptoms by addressing the underlying infection. It is applied across domains where additional symptomatic support is needed, and may assist in managing the microbial presence responsible for acute episodes of vaginitis. This focused approach contributes to easing the overall symptom load and supports the patient during difficult episodes by supporting management of the infectious process.

Ginalgin is relevant for managing symptom clusters that may become intense or disruptive, particularly those related to inflammatory or irritative states. It is applied in addressing key manifestations, including abnormal vaginal discharge, unpleasant odor, and localized irritation such as burning and itching. This may provide supportive relief when symptoms interfere with routine activities.

“The primary goal of this therapeutic category is to manage the infectious process and help ease pronounced symptoms, which may support the patient's day-to-day comfort.”

Quick Fact: Relief for Symptom Clusters The medication is relevant in clinical scenarios where patients experience multiple disruptive symptoms related to inflammatory or irritative states, including discharge, odor, and irritation.

Regulatory References

NIH MedlinePlus overview of metronidazole vaginal

Eligibility and Restrictions for Use

Who can and cannot use Ginalgin?

Population eligibility for Ginalgin (Metronidazole and Chlorquinaldol vaginal tablets) is defined by official regulatory criteria, primarily based on contraindications to its active ingredients.

Eligibility Status	Patient Population & Condition
Contraindicated	Patients with a known hypersensitivity or allergy to Metronidazole, Chlorquinaldol, or other nitroimidazole medicines.
	Patients who have taken Disulfiram within the last two weeks or who consume alcohol during treatment or for three days afterward.
	Patients diagnosed with Cockayne Syndrome due to the risk of severe hepatotoxicity.
Restricted Use	Pregnancy: Generally not recommended in the first trimester. Use in the second and third trimesters is conditional.
	Lactation: Use is associated with Metronidazole passing into breast milk; temporary cessation of breastfeeding may be recommended.
Conditional Use	Patients with severe hepatic impairment or a history of CNS disorders (e.g., seizures), requiring caution and careful monitoring.
	Patients with a history of blood dyscrasias or current vaginal candidiasis.
Not Established	Pediatric Population: Safety and efficacy are not established for use in girls who have not yet reached menarche (menstruation).

Eligibility is limited to adult women for the approved local treatment of susceptible infections. The medicine must not be used in absolutely contraindicated groups, and use is restricted in specific health conditions or physiological states as documented in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This profile outlines the officially documented interaction risks associated primarily with the Metronidazole component of Ginalgin, as detailed in regulatory prescribing information.

Interaction Restrictions and Timing

Classification	Interacting Substances and Required Constraint
Contraindicated	Disulfiram: Co-administration is prohibited due to the risk of psychotic reactions; a mandatory separation period of at least two weeks is required.
Substance Restriction	Alcohol (Ethanol/Propylene Glycol): Consumption is restricted during therapy and for a specified time following the final dose, typically 24 to 72 hours, due to the potential for a disulfiram-like reaction.

Exposure and Modification Risks

Interactions with certain medicinal products are officially classified based on their effect on drug concentrations:

Potentiation of Anticoagulants: Co-administration with Warfarin or other Coumarin anticoagulants is documented to potentiate the anticoagulant effect, which requires specific monitoring.
Increased Systemic Exposure: Agents like Cimetidine decrease Metronidazole plasma clearance through inhibition of metabolic enzymes, leading to increased systemic exposure and prolonged half-life. Similarly, Lithium concentrations are officially reported to become elevated, raising the risk of toxicity.
Decreased Exposure: Conversely, inducers of hepatic enzymes, such as Phenytoin or Phenobarbital, are documented to accelerate Metronidazole elimination, resulting in reduced plasma concentrations.

A population-specific constraint noted in regulatory documents applies to patients with Severe Hepatic Disease, where the reduced clearance of the active agent results in accumulation and a heightened risk of interaction.

Mechanism of Action

Bioactivation and Targeted DNA Destruction

This domain covers the action of Metronidazole, a prodrug whose mechanism is highly specific. The molecule enters susceptible organisms, like anaerobes and protozoa, where it is reduced by low-redox potential proteins (e.g., ferredoxin) to form a potent, cytotoxic nitroso radical anion. This radical directly attacks and fragments the microbial DNA, leading to the irreversible cessation of replication and synthesis. The resulting physiological effect is the selective destruction (bactericidal/antiprotozoal) of organisms that rely on this specific metabolic pathway.

Broad-Spectrum Cellular and Metabolic Disruption

This domain describes the non-selective antiseptic action of Chlorquinaldol. It operates through two primary avenues: first, by acting as a chelating agent to strip essential metal ions from microbial enzymes, inhibiting multiple metabolic pathways; and second, by directly disrupting the structural integrity and permeability of the microbial cell membrane. This dual attack leads to a general cellular and metabolic failure, producing a broad cytotoxic effect against various microbial forms, including bacteria and fungi.

Mechanistic Synergy and Environmental Limits

The combination of Metronidazole's DNA fragmentation and Chlorquinaldol's enzyme/membrane disruption results in diverse molecular targeting, which mechanically broadens the spectrum of susceptible microbial classes. However, this action is subject to the environmental constraint of Metronidazole, where the local presence of oxygen competes with the drug's activation pathway, reducing the efficacy of the anaerobic-targeting component.

Dosage and Administration Information

The use of Ginalgin, a combination medicine formulated as a Vaginal Tablet, is governed by principles concerning its local route, standardized dose, and fixed duration. The product contains 250 mg of Metronidazole and 100 mg of Chlorquinaldol per unit.

Administration Route and Dosing

The approved method is the local, intravaginal route, using the tablet as supplied for direct application. The standardized adult regimen involves applying one tablet once daily, a schedule designed to maintain consistent local therapeutic levels. This administration is preferably performed in the evening or before bedtime to promote retention and local action.

Duration and Special Conditions

Official instructions mandate a fixed, complete treatment duration, typically a 10-day course. It is a procedural requirement to complete the full course as prescribed, even if the condition appears to change prior to the final day.

Administration is subject to time-relationship constraints: treatment should generally be initiated two to four days after the end of menstruation, and the tablet’s use is typically avoided during the menstrual cycle itself. The medicine is not recommended for use in children and adolescents under 18 years of age. For a missed dose, the instruction is to administer the tablet as soon as possible, unless the next scheduled application is imminent, in which case the missed dose must be skipped to prevent double dosing.

Recent Clinical Evidence

Research evidence / Overview of studies for Ginalgin

Evidence for use in Bacterial Vaginosis (BV)

Research exploring the use of Ginalgin (Metronidazole and Chlorquinaldol vaginal tablets) for Bacterial Vaginosis (BV) primarily includes randomized controlled trials (RCTs) and studies that included other observational treatment groups. These trials were studied for periods of increased symptom activity in non-pregnant adult women. Researchers examined how symptoms evolved in the observed populations, monitoring patient-reported outcomes related to perceived discomfort, such as abnormal discharge and odor. They also monitored microbiological outcomes to measure shifts in the underlying bacterial environment.

These studies focused on short-term changes, generally assessing the initial period following the completion of the treatment course. Findings describe patterns observed in the studies related to the measurements of predefined clinical and microbiological outcomes. Some studies also explored patterns measured when the combination was observed alongside single-agent metronidazole or other anti-infective therapies, providing context but not individual predictions regarding the treatment approach.

Research in Mixed Vaginal Infections and General Infectious Vaginitis

Research has also examined Ginalgin in the context of conditions characterized by fluctuating or episodic manifestations. These investigations often rely on small-scale clinical studies and observational settings. In these observational settings, studies monitored outcomes related to overall physical discomfort and patient-reported outcomes describing episodic or acute changes. Research highlights changes measured during the study period, with findings indicated measured changes in localized symptoms in some observed populations. However, evidence derived from these settings often features modest sample sizes, meaning the evidence quality varies across studies, and the certainty remains low compared to the well-defined studies for BV.

Areas of Uncertainty and Research Gaps

Long-term outcomes are not fully established. Follow-up durations were limited in much of the available data. Recurrence patterns were noted across most BV treatments included in the research, and long-term effects for this specific combination are not fully established. The evidence base relies on the documented activity profile of Metronidazole, meaning the full, independent contribution of the Chlorquinaldol component to the patterns observed is not fully established.

Clinical studies primarily focused on a specific demographic: non-pregnant, symptomatic adult women. Consequently, the results apply only to the populations studied. Research exploring the use of Ginalgin in pregnant populations or adolescents is not fully established in the available key clinical evaluation studies. Data are still emerging, and certainty remains low in these areas.

Frequently Asked Questions (FAQ)

Common questions about Ginalgin (FAQ)

Q: What is the primary disease or condition Ginalgin is used to treat?

A: According to official product information, Ginalgin is indicated for the local treatment of certain vaginal infections. These conditions are typically caused by microorganisms susceptible to the drug’s active ingredients, such as anaerobic bacteria and protozoa.

Q: Is Ginalgin considered a prescription or an over-the-counter medicine?

A: Ginalgin is classified as a Prescription Only Medicine (POM). This classification is based on the active ingredients it contains and the need for medical guidance for its proper use and administration.

Q: Does Ginalgin typically cause weight gain or weight loss?

A: Weight changes are not commonly reported side effects listed in the product’s official documents. However, systemic absorption of one of the active agents has been associated in rare cases with reports of appetite loss, which may result in weight loss.

Q: Is it considered normal to feel a bit dizzy or lightheaded after starting Ginalgin?

A: Dizziness is a documented systemic side effect of Ginalgin, which occurs due to the partial absorption of its active ingredients into the body. Official sources classify this as a possible adverse reaction. Patients who experience this should monitor the symptom.

Q: Does Ginalgin affect the liver or kidneys?

A: Regulatory warnings mention that Ginalgin may be contraindicated or requires special caution for patients with a history of severe hepatic disease (liver failure). While kidney disease is not a primary contraindication for the local application, systemic use of the active agent requires caution with renal impairment.

Q: Can Ginalgin cause mood changes or increase anxiety?

A: Reports of adverse reactions affecting the nervous system include symptoms such as depression, confusion, and sleep disturbances. While these neurological effects are documented, anxiety or general mood changes are not specifically listed as primary adverse events in the official product information.

Q: Does Ginalgin commonly cause drowsiness or fatigue?

A: Systemic adverse reactions such as dizziness, sleep disturbances, and fatigue have been reported in connection with Ginalgin use. Regulatory documents categorize these as possible effects that may occur, though they are not always common.

Q: Can Ginalgin be taken on an empty stomach?

A: Ginalgin is a vaginal tablet intended for local, intravaginal use. Therefore, instructions regarding food intake, such as taking it on an empty stomach, are not relevant to its proper method of administration.

Q: Is it important to take Ginalgin at the exact same time every day?

A: Ginalgin is prescribed for use once daily, with a preference for administration in the evening or before bedtime. Taking the dose at approximately the same time each day is generally recommended to help maintain consistent local therapeutic levels.

Q: Is Ginalgin safe to use before driving or operating machinery?

A: The active ingredients in Ginalgin have the potential to cause central nervous system effects such as dizziness, confusion, and visual disturbances. Official product information notes that driving or operating machinery may be impaired if a patient experiences these effects.

Q: Does Ginalgin interact with common over-the-counter pain relievers like paracetamol or ibuprofen?

A: Official interaction lists primarily address prescription medications, and they do not typically include common over-the-counter pain relievers like paracetamol or ibuprofen. It is important that patients inform their prescriber of all medicines being used, including OTC products.

Q: Are there any foods or beverages that should be avoided when taking Ginalgin?

A: Alcohol consumption is strictly restricted and should be avoided during therapy and for a specified period (typically 24 to 72 hours) after the final dose due to the risk of a severe disulfiram-like reaction. Official documents do not specify any restrictions regarding common foods.

Q: Can Ginalgin affect the effectiveness of oral contraceptives (birth control pills)?

A: One of the active agents in Ginalgin is generally considered unlikely to reduce the effectiveness of most hormonal contraceptives. However, due to varying official guidance, some authorities recommend that patients consider using backup contraception.

Q: Can Ginalgin be used safely while breastfeeding?

A: The local, vaginal application results in reduced systemic exposure to the active agents compared to oral use. Official guidance indicates that one active agent, Metronidazole, is generally considered safe for use when breastfeeding a healthy, full-term infant, but caution and monitoring are advised.

Q: Is Ginalgin considered safe for use by the elderly population?

A: Official documents indicate that no specific dose adjustment is typically required for Ginalgin when it is prescribed for use in the elderly population. The standardized adult regimen is generally applicable.

Q: Where can I find summaries of the clinical trial evidence for Ginalgin?

A: Summaries of the clinical trials and research evidence can be accessed in official regulatory documents, such as the Summary of Product Characteristics (SmPC) provided by the official Medicines Agency. This information is also often available on governmental health research databases.

Q: What should be done if I suspect an overdose of Ginalgin?

A: In the event that a person suspects an overdose of Ginalgin, official documents indicate that immediate contact with a poison control center or seeking emergency medical attention is necessary.

Q: Is there a known effect of Ginalgin on fertility?

A: There is no clear evidence in humans to suggest that Ginalgin, when used as directed for the prescribed duration, reduces fertility. However, animal studies involving high systemic doses of one active agent have shown some potential adverse effects.

Q: What is the safety classification of Ginalgin?

A: The drug is often classified by the risk associated with its active agents, particularly regarding use during pregnancy. Official guidelines advise using Ginalgin during pregnancy only if it is strictly necessary or if the clinical benefit outweighs the potential risk.

How should Ginalgin be stored and disposed of?

The storage and disposal of Ginalgin (Metronidazole and Chlorquinaldol Vaginal Tablets) must strictly adhere to the conditions mandated by regulatory labeling to preserve product quality and safety.

Storage Requirements

Condition	Mandate
Temperature	Store below 86 F (30 C); do not freeze.
Protection	Keep in its original container, tightly closed, protected from light and moisture.
Safety	The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local regulations and procedures. Do not flush the vaginal tablets down a toilet or pour them down a sink unless specifically directed by local authorities. If a drug take-back program is unavailable, follow the general guidance to mix the medicine with an undesirable substance (such as coffee grounds) before discarding it in the household trash.

Ginalgin